PFS and OS was observed with A+V+C vs P+V+C in patients with PR, with 2-year PFS rates of 42.1% vs 24.6% and 2-year OS rates of 69.1% vs 56.1% with A+V+C vs P+V+C (table 1). In patients with CR, median PFS and OS were not yet reached in either arm, with 2-year PFS rates of 64.6% vs 59.8% and 2-year OS rates of 82.6% vs 82.8% with A+V+C vs P+V+C. PFS and OS outcomes were poor in both treatment arms in patients with SD, with 2-year PFS rates of 10.7% vs not estimable (NE) and 2-year OS rates of 66.6% vs 29.3% with A+V+C vs P+V+C. Conclusions PFS and OS improvement was observed for A+V+C vs P+V+C for patients who achieved CR. PR is associated with improved PFS and OS with both A+V+C and P+V+C. Further follow-up is required to determine the impact of A+V+C vs P+V+C on survival outcomes.

**Trial Registration** ClinicalTrials.gov, NCT02908672

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0301

### 302 A PHASE I TRIAL OF INTRATUMORAL PVSRIPO IN PATIENTS WITH UNRESECTABLE TREATMENT REFRACTORY MELANOMA

1Georgia Beasley, 1Nelle Farrow, 1Kareena Landa, 1Maria Angelica Seilm, 1Sin-Ho Jung, 1Darell Bigner, 1Andrea True Kelly, 1Smita Nair, 1Matthias Gromeier, 1April Salama. 1Duke University, DURHAM, NC, USA; 1Istari Oncology, Durham, NC, USA

**Background** While PD-1/PD-L1 antagonists have improved the prognosis for many patients with melanoma, the majority fail therapy. PVSRIPO is a novel immunotherapy consisting of a non-neurovirulent rhinovirus-poliovirus chimera that activates innate immunity to facilitate a targeted anti-tumor immune response. Preclinical data show that PVSRIPO plus anti-PD-1 therapy leads to a greater anti-tumor response than either agent alone, warranting clinical investigation.

**Methods** An open-label phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma (AJCC version 7 stage IIIb, IIIC, or IV) was performed. Eligible patients failed at least prior anti-PD-1 and BRAF/MEK (if BRAF mutant) therapy. The primary objective was to characterize the safety and tolerability of PVSRIPO. 12 patients in 4 cohorts received a total of 1, 2 (into 2 different lesions) or 3 (same lesion 3x or 3 different lesions) injections of PVSRIPO monotherapy, 21 days apart.

**Results** PVSRIPO injections were well tolerated with no SAEs or DLTs reported; all TEAEs were grade (G) 1 or 2 (grade 1 pruritus most common at 38%), with all but 2 PVSRIPO-related TEAEs localized to the injected or adjacent lesions (n=1 G1 hot flash, n=1 G1 fatigue). Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients >5 lesions), 4 of 12 patients (33%) achieved an objective response per irRC, including 4/6 (66%) who received 3 injections (maximum administered). Pathologic complete response (ie, no viable tumor detected in injected and non-injected lesions biopsied) was observed in 2 of 4 (50%) patients with in-transit disease. PVSRIPO response relative to time since prior anti-PD-1 exposure is summarized in table 1. Following study completion/PVSRIPO therapy, 10/12 patients (83%) again received immune checkpoint inhibitor (ICI)-based therapy and 6/12 patients (50%) remained progression free at the data cutoff.

**Conclusions** Intratumoral PVSRIPO was well tolerated. When taken together with preclinical data, the anti-tumor responses observed relative to prior or subsequent ICI therapy suggests that PVSRIPO, either alone or in combination with anti-PD-1, may be an effective treatment in anti-PD-1 refractory melanoma. An amendment exploring higher PVSRIPO dose levels is ongoing and a phase 2 study with and without anti-PD-1 in the refractory population is initiating.

**Ethics Approval** This study (NCT03712358) was approved by WIRB; ID 20181772.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0302

### 303 PHASE II TRIAL OF NEOADJUVANT NIVOLUMAB (NIVO) AND INTRATUMORAL (IT) CMP-001 IN HIGH-RISK RESECTABLE MELANOMA (NEO-C-NIVO): FINAL RESULTS

1Dwaker Davar*, 2Arivarasan Karunamurthy, 3Douglas Hartman, 3Richelle DeBlasio, 3Joe-Marc Chauvin, 1Quanquan Ding, 1Ornella Pagliano, 1Amy Rose, 1John Kirkwood, 1Hassane Zarour. 1Duke University, Durham, NC, USA; 2Istari Oncology, Durham, NC, USA; 3University of Pittsburgh, Pittsburgh, PA, USA

**Background** Neoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable melanoma (MEL) with durable relapse-free benefit, and increased circulating activated CD8+ T cells. 1, 2 CMP-001 is a type A CpG packaged within a virus-like particle that activates tumor-associated plasmacytoid dendritic cells (pDC) via TLR9 inducing type I interferons and anti-tumor CD8+ T cells. CMP-001/pembrolizumab produces durable anti-tumor responses in PD-1 refractory melanoma. 3 We previously reported preliminary evidence of efficacy of neoadjuvant IT CMP/Nivo in high-risk resectable MEL; and herein present final results on 30 evaluable patients.